What to do if you've been rejected for Mounjaro

The letter or email arrived and you weren't expecting it

You filled out the consultation carefully, answered every question honestly, and still got declined. That stings. For a lot of people, reaching the point of asking about Mounjaro took months of weighing it up, so being turned away (especially without a detailed explanation) feels deflating.

The first thing worth knowing is that rejection is not a moral verdict. Mounjaro carries a Black Triangle designation in the UK, meaning it is still under additional MHRA monitoring, and prescribers are obligated to assess every individual carefully. The NHS and private clinics are working from different rulebooks, so the reason for your particular rejection shapes what you can actually do next.

If the no came from the NHS, it almost certainly relates to the phased commissioning criteria. NHS England is rolling out tirzepatide in stages: the current cohort requires a BMI of 40 or above alongside four or more specific weight-related conditions from a defined list that includes high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. A second cohort covering BMI 35–39.9 with four or more of those conditions became available from around June 2026. Even if you meet the numbers on paper, every NHS patient must also enrol in a wraparound diet and activity programme, and GP practice participation in the new prescribing arrangement is optional, meaning your surgery may simply not yet be offering it. More detail on how Mounjaro works and who it is licensed for is worth reading alongside these NHS criteria.

If the rejection came from a private service, the reasons are more varied. A prescriber may have flagged a contraindication in your medical history, a concern about a concurrent medicine, or a BMI that sits below the licensed threshold without a qualifying weight-related condition. Private services follow the same SmPC eligibility rules (adults with a BMI of 30 or above, or 27 or above with at least one relevant condition) but each prescriber uses clinical judgement beyond those numbers.

The specific situations that most often lead to a private rejection

A few patterns come up repeatedly. The most straightforward is BMI: if yours sits below 27, Mounjaro is outside its licensed indication for weight management in the UK, and a responsible prescriber will not prescribe it regardless of how persistent the request. There is no clinical or legal route around this for weight management purposes.

Certain medical histories raise immediate flags. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) is a contraindication listed in the SmPC. Active or recent pancreatitis is another, in January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known, infrequent but potentially serious risk with GLP-1 medicines, which sharpened prescriber caution in this area. Severe gastrointestinal conditions, certain kidney concerns, and pregnancy or breastfeeding are also grounds for declining.

Transfer patients and those requesting a dose increase sometimes hit a different wall: the prescriber needs evidence of your current dose and treatment history before continuing, and if that documentation isn't provided, the consultation may be declined pending it. This isn't a permanent rejection; it is a request for information. If you've ever been curious about practical guidance for using Mounjaro safely, that page also touches on what documentation can help smooth a transfer request.

A smaller group is rejected because of a concurrent medicine that the prescriber wants to discuss further with a GP before proceeding, particularly oral contraceptives (because tirzepatide can reduce their absorption during the first four weeks of treatment and after each dose increase) or oral HRT. Again, this is often a timing issue rather than an absolute no.

What your actual options look like after a rejection

If the NHS turned you down because you don't yet meet the phased criteria, the most practical move is to speak to your GP about what the upcoming cohorts require and whether your health profile could qualify you in the next phase. If you don't want to wait (and many people don't) a regulated private route is available to those who meet the licensed criteria, without a referral or waiting list. The eligibility bar is lower than the NHS's current phased thresholds, though the prescriber still assesses your whole picture. You can check your eligibility through a free consultation and hear back from a GPhC-registered prescriber the same day.

If the rejection came from a private prescriber for a clinical reason, the right step is to understand which type of reason it was. Absolute contraindications won't change. But if it was a BMI that's close to the threshold, a medical history that's changed, or missing documentation, there may be a path forward once those details are resolved. If cost is part of what you're working through at this stage, it's worth checking whether a code for Mounjaro is available to you, as discounts can make a meaningful difference to what you pay.

It is also worth knowing that Mounjaro is not the only licensed option. Wegovy (semaglutide) is separately licensed for weight management in the UK, follows a different clinical pathway, and suits some people whose health profile makes tirzepatide less suitable. The weight-loss treatment overview sets out both options side by side. For people actively researching newer molecules, it can also be useful to understand whether retatrutide or Mounjaro might be the better fit, retatrutide is not yet licensed in the UK, but the comparison is informative for anyone tracking emerging options.

Our clinical team reviews every consultation personally. If you want to understand more about how the process works before starting, the FAQs cover the most common questions we hear. And if the cost picture matters to your planning, the context behind Eli Lilly's 2025 UK price changes is useful to understand, private Mounjaro prices rose considerably from September 2025, and knowing why helps you read the market more clearly. One question our prescribers hear most weeks from people who've been rejected elsewhere: "does my age affect whether I can get Mounjaro?" The answer, covered fully on the age and Mounjaro eligibility page, is more nuanced than a simple yes or no.

Being rejected once is not the last word. What it does tell you is that the service you approached was applying genuine clinical rigour, which, for a prescription medicine, is exactly what should happen.